Clinical trial

LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research

NCT02231164

Drugs and interventions used in this trial

4 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record docetaxel Normalized identity: docetaxelView linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention placebo Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record nintedanib Normalized identity: nintedanibView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research

Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2014-10-14

PhasePHASE3

Conditions

Carcinoma, Non-Small-Cell Lungunresolved

Interventions

docetaxelDRUG · verified · RxNorm: docetaxel

placeboDRUG

nintedanibDRUG · verified · RxNorm: nintedanib

Sponsors & collaborators

Boehringer Ingelheimlead sponsor

Mapped research locations

BangkokThailand1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02231164 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.